Silence Therapeutics PLC

XRP2

Company Profile

  • Business description

    Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

  • Contact

    72 Hammersmith Road
    LondonW14 8TH
    GBR

    T: +44 2034576900

    E: [email protected]

    https://www.silence-therapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    116

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,502.308.40-0.10%
CAC 407,873.8323.730.30%
DAX 4023,638.5672.020.31%
Dow JONES (US)42,140.43269.67-0.64%
FTSE 1008,602.922.06-0.02%
HKSE23,316.45208.180.90%
NASDAQ19,010.09301.741.61%
Nikkei 22537,957.45225.81-0.59%
NZX 50 Index12,807.9621.220.17%
S&P 5005,886.5542.360.72%
S&P/ASX 2008,257.0012.00-0.15%
SSE Composite Index3,374.690.18-0.01%

Market Movers